Aurinia Pharmaceuticals Inc (AUPH) — Capital Reinvestment Ratio

Latest as of March 2026: 0.00x

Aurinia Pharmaceuticals Inc (AUPH) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($32.56 Million) in capital expenditures ($39.00K). See AUPH equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x

Capex / Operating Cash Flow

Operating Cash Flow

$32.56 Million

USD

Capital Expenditures

$39.00K

USD

Data as of

Mar 2026

Most recent filing

Aurinia Pharmaceuticals Inc Capital Reinvestment Ratio (2024–2025)

This chart tracks Aurinia Pharmaceuticals Inc's Capital Reinvestment Ratio across 2 annual periods. Check Aurinia Pharmaceuticals Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Aurinia Pharmaceuticals Inc (2024–2025)

Year-by-year Capital Reinvestment Ratio for Aurinia Pharmaceuticals Inc from 2024 to 2025. For live market cap and broader valuation context, see Aurinia Pharmaceuticals Inc market cap and net worth.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change
2025	0.00x	$135.66 Million	$252.00K	▼ -70.7%
2024	0.01x	$44.39 Million	$281.00K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow